STOCK TITAN

Director at Neuraxis (NRXS) receives 21,598-share stock grant as compensation

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Watkins Bradley Mitchell reported acquisition or exercise transactions in this Form 4 filing.

Neuraxis, Inc. director Watkins Bradley Mitchell received a grant of 21,598 shares of common stock on January 22, 2026, as compensation for serving as an independent director. The shares were valued at $4.63 each, bringing his directly held stake to 46,335 shares after the award.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Watkins Bradley Mitchell

(Last) (First) (Middle)
11611 N. MERIDIAN ST, SUITE 330

(Street)
CARMEL IN 46032

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Neuraxis, INC [ NRXS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/22/2026 A 21,598 A $4.63(1) 46,335 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.
/s/ Bradley M. Watkins 02/26/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Neuraxis (NRXS) report for Watkins Bradley Mitchell?

Neuraxis reported that director Watkins Bradley Mitchell received a grant of 21,598 shares of common stock as compensation for his services as an independent director, increasing his directly held position to 46,335 shares after the transaction.

On what date did the Neuraxis (NRXS) director share grant occur?

The share grant to Neuraxis director Watkins Bradley Mitchell occurred on January 22, 2026. This date reflects when the 21,598 common shares were awarded to him as compensation for his role as an independent director of the company.

What was the share price used for the Neuraxis (NRXS) director stock grant?

The Neuraxis director stock grant used a price of $4.63 per share. This value applied to the 21,598 common shares awarded to Watkins Bradley Mitchell as compensation for his independent director services to the company.

How many Neuraxis (NRXS) shares does Watkins Bradley Mitchell own after this Form 4 transaction?

After the reported Form 4 transaction, Watkins Bradley Mitchell directly owns 46,335 shares of Neuraxis common stock. This total reflects his holdings following the grant of 21,598 shares as compensation for his independent director role.

Was the Neuraxis (NRXS) Form 4 transaction a market purchase or a grant?

The Neuraxis Form 4 transaction was a grant, not a market purchase. The 21,598 common shares were issued to director Watkins Bradley Mitchell as compensation for his services as an independent director, rather than being bought on the open market.

Does the Neuraxis (NRXS) Form 4 indicate director compensation in stock?

Yes, the Form 4 indicates director compensation in stock. Neuraxis issued 21,598 common shares to independent director Watkins Bradley Mitchell specifically as compensation for his board service, increasing his directly held ownership to 46,335 shares afterward.
Neuraxis Inc

NYSE:NRXS

NRXS Rankings

NRXS Latest News

NRXS Latest SEC Filings

NRXS Stock Data

60.61M
8.22M
Biotechnology
Electromedical & Electrotherapeutic Apparatus
Link
United States
CARMEL